<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448641</url>
  </required_header>
  <id_info>
    <org_study_id>SB-STR02</org_study_id>
    <nct_id>NCT02448641</nct_id>
  </id_info>
  <brief_title>Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke</brief_title>
  <acronym>ACTIsSIMA</acronym>
  <official_title>A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SanBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SanBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled study of stereotactic, intracranial injection of SB623 cells in patients with
      fixed motor deficits from ischemic stroke
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, sham-surgery controlled study of stereotactic, intracranial injection
      of SB623 cells in patients with fixed motor deficits from ischemic stroke. The study will be
      conducted at approximately 65 sites in the United States.

      Two cohorts, Group 1 (2.5 and 5 million SB623 cells combined) and Group 2 (sham placebo),
      will be included in this study. Subjects who are randomized into this study will receive
      either 2.5 million SB623 cells, 5 million SB623 cells or sham surgery at a 1:1:1
      randomization ratio. Randomization will be performed via an interactive web/voice response
      system (IXRS), stratified by Screening mRS score (recorded in the IXRS at the clinical site).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Scale Total Score Response; Modified Intent to Treat Population</measure>
    <time_frame>6 months</time_frame>
    <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fugl-Meyer Motor Scale Total Score Response; Per Protocol Population</measure>
    <time_frame>Month 6</time_frame>
    <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Additional Analysis, Fugl-Meyer Motor Scale (FMMS)</measure>
    <time_frame>Month 6</time_frame>
    <description>FMMS motor total score is summation of all 50 item scores with maximum of 100 points. The item scores are on 0 to 2 scale (0 = cannot perform, 1 = partial motion, 2 = full motion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale Response, Modified Intent to Treat Population</measure>
    <time_frame>Month 6</time_frame>
    <description>Modified Rankin Scale (mRS): This scale is used to measure the degree of disability or dependence in the daily activities of people who had suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Action Research Arm Test Response, Modified Intent to Treat Population</measure>
    <time_frame>Month 6</time_frame>
    <description>Action Research Arm Test (ARAT): The test was scored for left and right side separately. Performance on each item was rated on a 4-point ordinal scale ranging from: 3 (performed test normally in less than 5 seconds); 2 (completed test, but took abnormally long or had great difficult, with time varying from 5 to 60 seconds; 1 (performed test partially); 0 (could perform no part of the test). The ARAT is a 19-item measure divided into 4 subtests: Grasp subscale (with 6 items and a score range of 0 to 18); Grip subscale with 4 items and a score range of 0 to 12); Pinch subscale with 6 items and a score range of 0 to 18); Gross arm movement subscale (with 3 items and a score range of 0 to 9). The maximum score on the ARAT is 57 points (possible range 0 to 57) for each side.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Velocity Response Rate; Modified Intent to Treat Population</measure>
    <time_frame>Month 6</time_frame>
    <description>Gait Velocity was measured on a standard 10 meter walk. Two trials were tested and the average result from the two trails was used for analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Quality of Life Response</measure>
    <time_frame>baseline, Month 6</time_frame>
    <description>The Neurological Quality of Life (NeuroQOL) was used as a measure of change in the levels of Quality of Life, Satisfaction and Participation, secondary to improvements in the subject's upper and lower extremity motor function. NeuroQOL is summation of item scores for upper extremity (8 terms: score 8 - 40) and lower extremity (8 items: score 8 - 40) separately. The item scores are on a 1 to 5 scale (1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with little difficulty; 5 = without any difficulty). The result provided here shows NeuroQOL score converted to T-score as per conversion tables provided in Statistical Analysis Plan (SAP)-document Page no. 41 and 42. Referring to that, the range for Upper extremity T-score and Lower extremity T-score are 12.8 to 53.8 and 16.5 to 58.6 respectively. For any other information associated with NeuroQOL calculation, please refer SAP document dated December 21, 2018 provided under document section of this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Rating of Perceived Change Response Rate</measure>
    <time_frame>6 Months</time_frame>
    <description>Global Rating of Perceived Change from Baseline: Subjects and Clinicians were asked about perceived changes in their motor function by comparing &quot;how well they are doing compared to before the surgical procedure&quot;. The Subject Global Rating of Perceived Change was completed by the subject (or by the caregiver using the subject's answers). The following 7-point Likert scale was used: Score 7 (much better); Score 6 (a little better, meaningful); Score 5 (a little better, not meaningful); Score 4 (about the same); Score 3 (a little worse, not meaningful); Score 2 (a little worse, meaningful); Score 1 (much worse)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Chronic Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>SB623 Implant (2.5M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 million SB623 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SB623 Implant (5.0M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 million SB623 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB623 Implant (2.5M)</intervention_name>
    <description>2.5 million SB623 cells</description>
    <arm_group_label>SB623 Implant (2.5M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB623 Implant (5.0M)</intervention_name>
    <description>5 million SB623 cells</description>
    <arm_group_label>SB623 Implant (5.0M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham surgery</intervention_name>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years, inclusive

          2. Documented history of completed ischemic stroke in subcortical region of MCA or
             lenticulostriate artery with or without cortical involvement, with correlated findings
             by MRI

          3. Between 6 and 90 months (7.5 years) post-stroke, and having a chronic motor
             neurological deficit

          4. Neurological motor deficit substantially due to incident stroke

          5. Modified Rankin Score of 2-4

          6. Require Motricity Index 30-75 (UE Scale) or 27-74 (LE Scale)

          7. Able to undergo all planned neurological assessments

          8. Able and willing to undergo magneti resonance imaging (MRI) with contrast and computed
             tomography (CT)

          9. Agree that use of antiplatelet, anti-coagulant, or non-steroidal anti-inflammatory
             drugs to be determined by the local medical staff and in accordance with the ACCP 2012
             guideline &quot;Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy
             and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians
             Evidence-Based Clinical Practice Guidelines&quot;, if applicable , provided that no
             antiplatelet, anti-coagulant, or non-steroidal anti-inflammatory drugs are to be
             restarted post-surgery until after the Day 8 MRI is read and are determined to be safe
             to re-start

         10. Subjects must have had physical therapy prior to entry (and be willing to continue to
             the extent possible)

         11. Must be willing to discontinue herbal or non-traditional medicines for 1 week before
             and 1 week after the surgical procedure and be willing to continue to the extent
             possible

         12. Ability of patient or legal authorized representative to understand and sign an
             Informed Consent

        Exclusion Criteria:

          1. History or presence of any other major neurological disease other than stroke

          2. Cerebral infarct size &gt;150 cm3 measured by MRI

          3. Primary intracerebral hemorrhage

          4. Myocardial infarction within prior 6 mos.

          5. Malignancy unless in remission &gt;5 yrs.

          6. Clinically significant finding on MRI of brain not related to stroke

          7. Any seizures in the 3 months prior to Screening

          8. More than 5 degrees of contracture at shoulder, elbow, wrist, fingers, hip, knee and
             ankle

          9. Other neurologic, neuromuscular or orthopedic disease that limits motor function

         10. Uncontrolled systemic illness, including, but not limited to: hypertension; diabetes;
             renal, hepatic, or cardiac failure

         11. Positive findings on tests for occult malignancy, unless a non-malignant etiology is
             confirmed

         12. Uncontrolled major psychiatric illness, including depression symptoms (CESD R Scale of
             ≥16 is exclusionary)

         13. Total bilirubin &gt;1.9 mg/dL at Screening

         14. Serum creatinine &gt;1.5 mg/dL at Screening

         15. Hemoglobin &lt;10.0 g/dL at Screening

         16. Absolute neutrophil count &lt;2000 /mm3 at Screening

         17. Absolute lymphocytes &lt;800 /mm3 at Screening

         18. Platelet count &lt;100,000 /mm3 at Screening

         19. Liver disease supported by AST (SGOT) or ALT (SGPT) ≥2.5 x upper limit of normal at
             Screening

         20. Serum calcium &gt;11.5 mg/dL at Screening

         21. International Normalized Ratio of Prothrombin Time (INR) &gt;1.2 at Screening if the
             patient does not take anticoagulants; for patients on anticoagulants, INR must be
             confirmed to be ≤1.2 prior to surgery

         22. Presence of craniectomy or other contraindication to stereotactic surgery

         23. Participation in any other investigational trial within 4 weeks of initial screening
             and within 7 weeks of Baseline visit

         24. Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other
             interventional treatments for spasticity (except bracing and splinting) 16 weeks prior
             to the Baseline visit

         25. Substance use disorder (per DSM-V criteria, including drug or alcohol)

         26. Contraindications to head MRI (with constrast) or CT

         27. Pregnant or lactating

         28. Female patients of childbearing potential unwilling to use an adequate birth control
             method during the 12 months of the study

         29. Any other condition or situation that the investigator believes may interfere with the
             safety of the subject or the intent and conduct of the study

         30. Any prior SB623 cell implantation and/or any prior stem cell treatment for stroke or
             other reason regardless of mode of administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Steinberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Hospital and Clinics, School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (Surgical/Assessment)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenoscience, Inc. (Assessment)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of Southern California (Assessment)</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rancho Los Amigos National Rehab Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center (Assessment)</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>95710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center (Assessment/Surgical)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine (Assessment)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westview Clinical Research (Assessment)</name>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <zip>92870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center (Assessment)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. John's Health Center (Surgical)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Johns Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care (Surgical/Assessment)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Institute for Clinical Research (Assessment)</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar National Rehabilitation Hospital (Assessment)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine (Assessment/Surgical)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroMedical Research Institute (Assessment)</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medsol Clinical Research Center (Assessment)</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurostudies, Inc. (Assessment)</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida (Assessment)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital (Assessment)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital (Surgical)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Research and Education (Assessment)</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital (Surgical)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Assessment)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Surgical)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology, Ltd. (Assessment)</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Healthcare System (Assessment)</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Medical Research, Elkhart Clinic (Assessment)</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (Surgical)</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas Institute of Research (Assessment)</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital (Surgical)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Clinical Trials Unit (Assessment)</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroMedical Clinic of Central Louisiana (Assessment)</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Surgical)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University (Assessment)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System (Assessment)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey Medical School (Assessment)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center (Surgical/Assessment)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Burke Rehabilitation Hospital (Assessment)</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Rehabilitation (Assessment)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neuroscience Associates, Inc. (Assessment)</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology and Neuroscience Associates</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Case Medical Center (Surgical)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toledo Medical Center (Assessment)</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moss Rehab (Assessment)</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania (Assessment)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital (Surgical)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Comprehensive Stroke Center (Assessment)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (Surgical/Assessment))</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates (Assessment)</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (Surgical)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Center for Neurologic Research (Assessment)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical School</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston (Assessment/Surgical)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospitals (Assessment)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <results_first_submitted>December 20, 2019</results_first_submitted>
  <results_first_submitted_qc>April 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2020</results_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>chronic stroke</keyword>
  <keyword>fixed motor deficits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02448641/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT02448641/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total 302 subjects were enrolled in the study. Of the 302 subjects who were screened, 163 were randomized; 52 subjects to receive sham surgery, 55 subjects to receive 2.5 million SB623 cells, and 56 subjects to receive 5 million SB623 cells.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SB623 Implant (2.5M)</title>
          <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
        </group>
        <group group_id="P2">
          <title>SB623 Implant (5.0M)</title>
          <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
        </group>
        <group group_id="P3">
          <title>Sham Control</title>
          <description>Sham surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SB623 Implant (2.5M)</title>
          <description>2.5 million SB623 cells</description>
        </group>
        <group group_id="B2">
          <title>SB623 Implant (5.0M)</title>
          <description>5 million SB623 cells</description>
        </group>
        <group group_id="B3">
          <title>Sham Control</title>
          <description>Sham surgery</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="11.08"/>
                    <measurement group_id="B2" value="58.9" spread="9.99"/>
                    <measurement group_id="B3" value="55.2" spread="11.57"/>
                    <measurement group_id="B4" value="57.2" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fugl-Meyer Motor Scale Total Score Response; Modified Intent to Treat Population</title>
        <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery
Sham surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Fugl-Meyer Motor Scale Total Score Response; Modified Intent to Treat Population</title>
          <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fugl-Meyer Motor Scale Total Score Response; Per Protocol Population</title>
        <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery
Sham surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Fugl-Meyer Motor Scale Total Score Response; Per Protocol Population</title>
          <description>Fugl-Meyer Motor Scale (FMMS) Motor Total Score: The FMMS is used as a clinical measure of body function impairment after stroke that assessed several dimensions of motor impairment, including range of motion in both upper and lower limbs, including reflex activity, volitional movement, and co-ordination. The upper extremity subscale (33 items) and lower extremity subscale (17 items) were assessed for determination of efficacy. The FMMS is an ordinal scale that has 3 points for each item. The upper limb is scored between 0 and 66 points and the lower limb is scored between 0 and 34 points. The FMMS motor total score range from 0 (hemiplegia) to a maximum of 100 points (normal motor performance).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Additional Analysis, Fugl-Meyer Motor Scale (FMMS)</title>
        <description>FMMS motor total score is summation of all 50 item scores with maximum of 100 points. The item scores are on 0 to 2 scale (0 = cannot perform, 1 = partial motion, 2 = full motion)</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5 M)</title>
            <description>2.5 million SB623 cells SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5.0 million SB623 cells SB623 Implant (5.0M): 5.0 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Surgery</title>
            <description>Sham surgery: Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Additional Analysis, Fugl-Meyer Motor Scale (FMMS)</title>
          <description>FMMS motor total score is summation of all 50 item scores with maximum of 100 points. The item scores are on 0 to 2 scale (0 = cannot perform, 1 = partial motion, 2 = full motion)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="16.83"/>
                    <measurement group_id="O2" value="45.8" spread="15.07"/>
                    <measurement group_id="O3" value="47.2" spread="13.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="18.63"/>
                    <measurement group_id="O2" value="49.2" spread="17.97"/>
                    <measurement group_id="O3" value="50.8" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Between-group Effect size is calculated as the lease square [LS] mean difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2959</p_value>
            <method>Regression, Logistic</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
            <estimate_desc>The LSM difference (SE) from the sham surgery group was 1.2 (1.18), with a 95% CI of (-1.1, 3.6), an effect size of 0.19, and a p-value of 0.2959</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Scale Response, Modified Intent to Treat Population</title>
        <description>Modified Rankin Scale (mRS): This scale is used to measure the degree of disability or dependence in the daily activities of people who had suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery Group</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Response, Modified Intent to Treat Population</title>
          <description>Modified Rankin Scale (mRS): This scale is used to measure the degree of disability or dependence in the daily activities of people who had suffered a stroke. The mRS is an ordinal scale from 0 (no symptoms at all) to 5 (severe disability; requiring constant nursing care and attention, bedridden, incontinent) with a sixth category of death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Action Research Arm Test Response, Modified Intent to Treat Population</title>
        <description>Action Research Arm Test (ARAT): The test was scored for left and right side separately. Performance on each item was rated on a 4-point ordinal scale ranging from: 3 (performed test normally in less than 5 seconds); 2 (completed test, but took abnormally long or had great difficult, with time varying from 5 to 60 seconds; 1 (performed test partially); 0 (could perform no part of the test). The ARAT is a 19-item measure divided into 4 subtests: Grasp subscale (with 6 items and a score range of 0 to 18); Grip subscale with 4 items and a score range of 0 to 12); Pinch subscale with 6 items and a score range of 0 to 18); Gross arm movement subscale (with 3 items and a score range of 0 to 9). The maximum score on the ARAT is 57 points (possible range 0 to 57) for each side.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery Group (Control)</description>
          </group>
        </group_list>
        <measure>
          <title>Action Research Arm Test Response, Modified Intent to Treat Population</title>
          <description>Action Research Arm Test (ARAT): The test was scored for left and right side separately. Performance on each item was rated on a 4-point ordinal scale ranging from: 3 (performed test normally in less than 5 seconds); 2 (completed test, but took abnormally long or had great difficult, with time varying from 5 to 60 seconds; 1 (performed test partially); 0 (could perform no part of the test). The ARAT is a 19-item measure divided into 4 subtests: Grasp subscale (with 6 items and a score range of 0 to 18); Grip subscale with 4 items and a score range of 0 to 12); Pinch subscale with 6 items and a score range of 0 to 18); Gross arm movement subscale (with 3 items and a score range of 0 to 9). The maximum score on the ARAT is 57 points (possible range 0 to 57) for each side.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gait Velocity Response Rate; Modified Intent to Treat Population</title>
        <description>Gait Velocity was measured on a standard 10 meter walk. Two trials were tested and the average result from the two trails was used for analysis</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery
Sham surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Velocity Response Rate; Modified Intent to Treat Population</title>
          <description>Gait Velocity was measured on a standard 10 meter walk. Two trials were tested and the average result from the two trails was used for analysis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Quality of Life Response</title>
        <description>The Neurological Quality of Life (NeuroQOL) was used as a measure of change in the levels of Quality of Life, Satisfaction and Participation, secondary to improvements in the subject's upper and lower extremity motor function. NeuroQOL is summation of item scores for upper extremity (8 terms: score 8 - 40) and lower extremity (8 items: score 8 - 40) separately. The item scores are on a 1 to 5 scale (1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with little difficulty; 5 = without any difficulty). The result provided here shows NeuroQOL score converted to T-score as per conversion tables provided in Statistical Analysis Plan (SAP)-document Page no. 41 and 42. Referring to that, the range for Upper extremity T-score and Lower extremity T-score are 12.8 to 53.8 and 16.5 to 58.6 respectively. For any other information associated with NeuroQOL calculation, please refer SAP document dated December 21, 2018 provided under document section of this study.</description>
        <time_frame>baseline, Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5 M)</title>
            <description>2.5 million SB623 cells SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5.0 million SB623 cells SB623 Implant (5.0M): 5.0 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Surgery</title>
            <description>Sham surgery: Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Quality of Life Response</title>
          <description>The Neurological Quality of Life (NeuroQOL) was used as a measure of change in the levels of Quality of Life, Satisfaction and Participation, secondary to improvements in the subject's upper and lower extremity motor function. NeuroQOL is summation of item scores for upper extremity (8 terms: score 8 - 40) and lower extremity (8 items: score 8 - 40) separately. The item scores are on a 1 to 5 scale (1 = unable to do; 2 = with much difficulty; 3 = with some difficulty; 4 = with little difficulty; 5 = without any difficulty). The result provided here shows NeuroQOL score converted to T-score as per conversion tables provided in Statistical Analysis Plan (SAP)-document Page no. 41 and 42. Referring to that, the range for Upper extremity T-score and Lower extremity T-score are 12.8 to 53.8 and 16.5 to 58.6 respectively. For any other information associated with NeuroQOL calculation, please refer SAP document dated December 21, 2018 provided under document section of this study.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Baseline, Upper Extremity Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.60" spread="11.565"/>
                    <measurement group_id="O2" value="27.31" spread="10.950"/>
                    <measurement group_id="O3" value="27.10" spread="13.493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 6, Upper Extremity Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.92" spread="11.557"/>
                    <measurement group_id="O2" value="27.24" spread="10.600"/>
                    <measurement group_id="O3" value="27.37" spread="11.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Baseline, Lower Extremity Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.39" spread="7.119"/>
                    <measurement group_id="O2" value="37.56" spread="6.365"/>
                    <measurement group_id="O3" value="41.93" spread="5.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Month 6, Lower Extremity Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.01" spread="8.479"/>
                    <measurement group_id="O2" value="40.37" spread="6.884"/>
                    <measurement group_id="O3" value="43.21" spread="7.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis: NeuroQOL score for the Upper Extremity Function (Between-group Effect size is calculated as the lease square [LS] mean difference)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7788</p_value>
            <method>Regression, Logistic</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.90</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
            <estimate_desc>The LSM difference (SE) from the sham surgery group was -0.36 (1.283), with a 95% CI of (-2.90, 2.17), an effect size of 0.05, and a p-value of 0.7788.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis: NeuroQOL score for Lower Extremity Function (Between-group Effect size is calculated as the lease square [LS] mean difference)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5347</p_value>
            <method>Regression, Logistic</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
            <estimate_desc>The LSM difference (SE) from the sham surgery group was 0.58 (0.934), with a 95% CI of (-1.26, 2.43), an effect size of 0.11, and a p-value of 0.5347.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Rating of Perceived Change Response Rate</title>
        <description>Global Rating of Perceived Change from Baseline: Subjects and Clinicians were asked about perceived changes in their motor function by comparing &quot;how well they are doing compared to before the surgical procedure&quot;. The Subject Global Rating of Perceived Change was completed by the subject (or by the caregiver using the subject's answers). The following 7-point Likert scale was used: Score 7 (much better); Score 6 (a little better, meaningful); Score 5 (a little better, not meaningful); Score 4 (about the same); Score 3 (a little worse, not meaningful); Score 2 (a little worse, meaningful); Score 1 (much worse)</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SB623 Implant (2.5M)</title>
            <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
          </group>
          <group group_id="O2">
            <title>SB623 Implant (5.0M)</title>
            <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
          </group>
          <group group_id="O3">
            <title>Sham Control</title>
            <description>Sham surgery
Sham surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Global Rating of Perceived Change Response Rate</title>
          <description>Global Rating of Perceived Change from Baseline: Subjects and Clinicians were asked about perceived changes in their motor function by comparing &quot;how well they are doing compared to before the surgical procedure&quot;. The Subject Global Rating of Perceived Change was completed by the subject (or by the caregiver using the subject's answers). The following 7-point Likert scale was used: Score 7 (much better); Score 6 (a little better, meaningful); Score 5 (a little better, not meaningful); Score 4 (about the same); Score 3 (a little worse, not meaningful); Score 2 (a little worse, meaningful); Score 1 (much worse)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety was monitored throughout the study. The adverse event reporting period for this trial begins upon informed consent and ends 12 months after the administration of SB623, or at Early Termination. Also, an external Data Safety Monitoring Board (DSMB) was utilized to review safety data, including clinical symptoms, laboratory findings, and MRI brain imaging. The DSMB will review ongoing study data within one month of the enrollment of subjects at the 25%, 50%, and 75% of the total population.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SB623 Implant (2.5M)</title>
          <description>2.5 million SB623 cells
SB623 Implant (2.5M): 2.5 million SB623 cells</description>
        </group>
        <group group_id="E2">
          <title>SB623 Implant (5.0M)</title>
          <description>5 million SB623 cells
SB623 Implant (5.0M): 5 million SB623 cells</description>
        </group>
        <group group_id="E3">
          <title>Sham Control</title>
          <description>Sham surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="35" subjects_at_risk="55"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="56"/>
                <counts group_id="E3" events="35" subjects_affected="32" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="12" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bijan Nejadnik M.D.; Chief Medical Officer</name_or_title>
      <organization>SanBio, Inc.</organization>
      <phone>650-625-2205</phone>
      <email>Bijan.Nejadnik@sanbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

